Hypofractionated, Dose Escalation Radiotherapy for High-Risk Prostate Cancer: the safety analysis of the Prostate Cancer Study-5 (PCS-5), a GROUQ led phase III trial.

This is the first study of moderate HF dose escalated RT in exclusively high-risk prostate cancer patients treated with long-term ADT and pelvic RT. Although our data was not analyzed as a non-inferiority, our results demonstrate that moderately HF-RT is well-tolerated and similar to SF-RT at 2 years and could be considered as an alternative to SF-RT.